Viyash Scientific Q3 FY26 Revenue ₹858.4 Cr, EBITDA ₹185.4 Cr, up 10.9% & 64.4%
Viyash Scientific reported Q3 FY26 revenues of ₹858.4 crore, up 10.9%, and EBITDA of ₹185.4 crore, up 64.4%. For 9M FY26, revenues increased by 11.9% to ₹2,500.4 crore, with EBITDA up 58% to ₹502.4 crore. PAT for 9M FY26 surged by 230%. Net Debt/EBITDA ratio is 0.38x.
The announcement details significant financial performance improvements, including substantial growth in revenue, EBITDA, and PAT, as well as a strengthened balance sheet. This directly impacts investor perception and the company's valuation.
The company reported strong year-over-year growth in revenue and EBITDA for both the quarter and the nine-month period. Profitability also saw significant increases, and the company highlighted a strong balance sheet and positive outlook post-merger.
Viyash Scientific Limited (formerly Sequent Scientific Limited) has announced its unaudited standalone and consolidated financial results for the quarter ended December 31, 2025. This marks the first quarter reporting on a combined basis post-merger.
For the third quarter of Fiscal Year 2026 (Q3 FY26), the company reported revenues of ₹8,584 million (₹858.4 crore), an increase of 10.9% compared to the same period last year. EBITDA stood at ₹1,854 million (₹185.4 crore), showing a significant growth of 64.4%. The Profit After Tax (PAT) for Q3 FY26 increased by 15.5%, even after accounting for exceptional merger-related costs.
For the nine-month period of Fiscal Year 2026 (9M FY26), revenues grew by 11.9% to ₹25,004 million (₹2,500.4 crore), and EBITDA increased by 58% to ₹5,024 million (₹502.4 crore). The PAT for the nine-month period saw a substantial rise of 230%. The company also reported a Net Debt to EBITDA ratio of 0.38x, reflecting a strengthened balance sheet after the pre-closure of high-cost debt.
Dr. Hari Babu Bodepudi, Managing Director and Group CEO, commented, "The results of Q3FY25-26 are an indication of the actions we have taken and the momentum we have built across the last few quarters, working as one team. Revenue, margins, profitability all have continued to show strong growth on the back of new product introductions, cost improvement and synergies across our business units. We have a strong balance sheet and market position and are geared up for capturing the market opportunity in the next 3-5 years. The merger is starting to generate benefits across R&D, manufacturing and front-end, all of which make us very excited for the journey ahead."
The company will hold an earnings call on February 06, 2025, at 17:30 IST to discuss the performance and answer investor queries. Viyash Scientific Limited is an integrated pharmaceutical company with businesses in formulations, APIs, and CDMO services for human and animal health, serving customers in over 100 countries.
What to do with a filing like this
Viyash Scientific Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Viyash Scientific Limited. Read the original for the full detail.